
Ritedose Pharmaceuticals Launches Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)
COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons of 60 vials. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.